Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide) for Heart Failure

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Heart Failure
Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide) - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether or not diuretic drugs given to heart failure patients work better when they are tailored to the patient's individual needs.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Heart Failure

Study Objectives

4 Primary · 1 Secondary · Reporting Duration: 6 hours

6 hours
Accuracy of prediction of mechanistic sub types of DR using universally available laboratory tests
Diuretics
Change in total 6-hour sodium output between observational and randomized intervention study days
Prediction of mechanistic sub types of DR
Prevalence of mechanistic sub types of Diuretic Resistance (DR) as defined by cutoff values of change in fractional excretion of lithium

Trial Safety

Safety Progress

1 of 3

Other trials for Heart Failure

Trial Design

3 Treatment Groups

Observational Arm
1 of 3
Increased Intravenous Loop Diuretic (Bumetanide or Furosemide)
1 of 3
Loop Diuretic (Bumetanide or Furosemide) + IV Chlorothiazide
1 of 3
Active Control
Experimental Treatment

458 Total Participants · 3 Treatment Groups

Primary Treatment: Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide) · No Placebo Group · Phase 1

Increased Intravenous Loop Diuretic (Bumetanide or Furosemide)
Drug
Experimental Group · 1 Intervention: Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide) · Intervention Types: Drug
Loop Diuretic (Bumetanide or Furosemide) + IV Chlorothiazide
Drug
Experimental Group · 1 Intervention: IV Chlorothiazide · Intervention Types: Drug
Observational ArmNoIntervention Group · 1 Intervention: Observational Arm · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 hours

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,666 Previous Clinical Trials
21,074,332 Total Patients Enrolled
27 Trials studying Heart Failure
52,557 Patients Enrolled for Heart Failure
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,576 Previous Clinical Trials
46,968,123 Total Patients Enrolled
193 Trials studying Heart Failure
677,069 Patients Enrolled for Heart Failure
Jeffrey Testani, MDPrincipal InvestigatorYale University
3 Previous Clinical Trials
81 Total Patients Enrolled
2 Trials studying Heart Failure
81 Patients Enrolled for Heart Failure

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a clinical diagnosis of ADHF with at least one objective sign of volume overload.
You are currently taking IV loop diuretics and you are projected to need additional IV diuretics for at least 3 days with the goal of significant fluid removal (>1L net fluid loss/day).

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: October 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.